CD44 Antikörper
Kurzübersicht für CD44 Antikörper (ABIN3025607)
Target
Alle CD44 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
Klon
-
-
Aufreinigung
- Protein G affinity chromatography
-
Immunogen
- Stimulated human leukocytes were used as the immunogen for this anti-CD44 antibody.
-
Isotyp
- IgG2a kappa
-
-
-
-
Applikationshinweise
-
The optimal dilution of the anti-CD44 antibody for each application should be determined by the researcher.
1. Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Flow Cytometry: 0.5-1 μg/million cells in 0.1ml,Immunofluorescence: 0.5-1 μg/mL,Functional Studies: Order Ab without BSA/azide,Western blot: 0.5-1 μg/mL,Immunohistochemistry (FFPE): 0.25-0.5 μg/mL for 30 min at RT (1),Prediluted format: incubate for 30 min at RT (2) -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1 mg/mL
-
Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
-
Konservierungsmittel
- Azide free
-
Lagerung
- 4 °C,-20 °C
-
Informationen zur Lagerung
- Store the anti-CD44 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
-
- CD44
-
Andere Bezeichnung
- CD44
-
Hintergrund
- Recognizes a cell surface glycoprotein of 80-95 kDa (CD44) on lymphocytes, monocytes, and granulocytes. Its epitope is resistant to digestion by trypsin and chymotrypsin. The CD44 family of glycoproteins exists in a number of variant isoforms, the most common being the standard 85-95 kDa or hematopoietic variant (CD44s). Higher molecular weight isoforms are described in epithelial cells (CD44v), which are believed to function in intercellular adhesion and stromal binding. CD44 immunostaining is commonly used for the discrimination of urothelial transitional cell carcinoma in-situ from non-neoplastic changes in the urothelium.
-
Pathways
- Glycosaminoglycan Metabolic Process, Autophagie, Negative Regulation of intrinsic apoptotic Signaling
Target
-